Effect of 4-aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial (Q40484322)

20 September 2017

title

Effect of 4-aminopyridine on gait in ambulatory spinal cord injuries: a double-blind, placebo-controlled, crossover trial (English)

1 reference

20 September 2017

0 references

DeForge D

1

1 reference

20 September 2017

Nymark J

2

1 reference

20 September 2017

Lemaire E

3

1 reference

20 September 2017

Gardner S

4

1 reference

20 September 2017

Hunt M

5

1 reference

20 September 2017

Martel L

6

1 reference

20 September 2017

Curran D

7

1 reference

20 September 2017

Barbeau H

8

1 reference

20 September 2017

publication date

1 December 2004

1 reference

20 September 2017

1 reference

20 September 2017

volume

42

1 reference

20 September 2017

issue

12

1 reference

20 September 2017

page(s)

674-685

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.sc.3101653

20 September 2017

exact match

0 references

cites work

Demyelination in spinal cord injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

The current status of studies of aminopyridines in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

Intrathecal administration of 4-aminopyridine in chronic spinal injured patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

Intravenous infusion of 4-AP in chronic spinal cord injured subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

Randomized trial of 4-aminopyridine in patients with chronic incomplete spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

Crossover and self-controlled designs in clinical research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

Gait patterns of elderly men with trans-tibial amputations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

Safety and efficacy of 4-aminopyridine in humans with spinal cord injury: a long-term, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

Absorption characteristics of sustained-release 4-aminopyridine (fampridine SR) in patients with chronic spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

Effect of 4-aminopyridine on axonal conduction-block in chronic spinal cord injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

Effects of 4-aminopyridine on demyelinated axons, synapses and muscle tension

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

Different effects of 4-aminopyridine on sensory and motor fibers: pathogenesis of paresthesias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

Sustained improvements in neurological function in spinal cord injured patients treated with oral 4-aminopyridine: three cases

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

4-Aminopyridine in chronic spinal cord injury: a controlled, double-blind, crossover study in eight patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

Randomized double-blind crossover trial of fampridine-SR (sustained release 4-aminopyridine) in patients with incomplete spinal cord injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

4-Aminopyridine alters gait characteristics and enhances locomotion in spinal cord injured humans.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

Relationship between static muscle strength deficits and spasticity in stroke patients with hemiparesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

Muscular weakness assessment: use of normal isometric strength data. The National Isometric Muscle Strength (NIMS) Database Consortium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

Kinematic and EMG patterns during slow, free, and fast walking

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

A dynamic EMG profile index to quantify muscular activation disorder in spastic paretic gait

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

Effects of 4-aminopyridine on motor evoked potentials in patients with spinal cord injury

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

The combined effects of clonidine and cyproheptadine with interactive training on the modulation of locomotion in spinal cord injured subjects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.SC.3101653

7 January 2021

Identifiers

DOI

10.1038/SJ.SC.3101653

1 reference

20 September 2017

1 reference